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ABSTRACT 
The use of statins has scaled up to become one of the most prescribed medicines in the 
world and have been very useful in the manegement of cardiovascular diseases and 
related mortality. The disclosure of their chemical structure similar to that of hydroxy 
methyl glutaryl-CoA (HMG-CoA) revealed their ability to compete with and inhibit the 
rate-limiting enzyme HMG-CoA reductase that catalyzes the synthesis of mevalonate, 
which then serves as the precursor for isoprenoids and cholesterol in the mevalonate 
pathway. While most of the effects of statins are associated with the lowering of cellular 
cholesterol levels, it is clear that they also blunt the non-sterol branch of the mevalonate 
pathway, decreasing formation of isoprenoids and altering protein-prenylation, a critical 
event in the posttranslational modulation of proteins involved in the regulation of cell 
cylce progression, proliferation and signaling pathways. Randomized controlled trials for 
the prevention of cardiovascular diseases indicated that statins elicited provocative and 
unexpected benefits for reducing a number of different types of cancers, including 
colorectal carcinoma, melanoma, prostate and hepatocellular carcinoma, although in 
other cancer types the preclinical expectations of statins were dissapointing. In this 
review, we will describe the evidence and mechanisms underlying the potential beneficial 
use of statins and the role of protein prenylation in cancer prevention. Of relevance, the 
combination of statins with other anti cancer drugs may be a significant asset in 
malignancies resistant to current therapy. 
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INTRODUCTION 
Statins are a class of small molecules that lower cholesterol levels by inhibiting the rate-
limiting enzyme hydroxymethylglutaryl-CoA (HMG-CoA) reductase, which plays a 
central role in the production of cholesterol in the liver. The screening of fungal extracts 
for inhibitors of cholesterol biosynthesis led to the discovery in 1976 of compacting, also 
known as mevastatin, as the first small molecule that blocked the conversion of radiactive 
acetate in cholesterol in rat liver membranes[1]. The mechanism of action of this 
pioneering statin involved the competitive inhibition of HMG-Co reductase, which 
catalyzes the conversion of HMG-CoA into mevalonate [2]. Because statins are similar to 
HMG-CoA on a molecular level they take the place of HMG-CoA in the enzyme and 
reduce the rate by which it is able to produce mevalonate. Due to the critical role of 
cholesterol as a constituent of atherosclerotic plaques lining the walls of blood vessels 
and the association between increased cholesterol and cardiovascular disease, the use of 
statins to reduced plasma cholesterol levels has scaled up to become one of the most 
prescribed medicines in the world [3]. One of the benefits associated with the use of 
statins is obviously linked to decrease incidents of cardivascular events and heart attacks. 
In addition, increasing evidence in preclinical and epidemiological studies have indicated 
that another potential benefit of statins use is associated with lower incidence of cancer 
development, particularly colorectal carcinoma, melanoma, prostate and hepatocellular 
carcinoma [4]. Even though this outcome indicate a critical role for cholesterol lowering 
in the potential beneficial association of statins and cancer prevention, due to the nature 
of the mevalonate pathway the effect of statins are beyond just preventing cholesterol 
synthesis. Indeed, there are several potential mechanisms whereby statins could influence 
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the incidence and progression of cancer development and therapy response, including the 
regulation of non-sterol components that are synthesized in the mevalonate pathway 
including dolichol, ubiquinol and the isoprenoids farnesol and geranylgeraniol, which in 
turn regulate the function of key proteins involved in cell growth and proliferation [5]. In 
addition, statins inhibit the activation of the proteasome pathway, contributing to the 
maintenance of proteins that block cell cycle. Moreover, through cholesterol 
downregulation, statins may also regulate the function of the Hedgehog, a signaling 
pathway that besides its critical function as a morphogen can promote carcinogenesis as 
well. Hence in this review, we will briefly cover the evidence for the role of statins in 
cancer prevention, particularly colorectal carcinoma, pancreas and hepatocellular 
carcinoma, focusing on the mevalonate pathway and protein prenylation to fully 
understand the actions of statins beyond cholesterol regulation.  
STATINS AND THE MEVALONATE PATHWAY 
Through the pionering work of Akira Endo [1], the molecular mechanism of statins is the 
inhibition of HMG-CoA reductase, which sits at the apex of the molecular pathway of 
cholesterol synthesis in the so-called mevalonate pathway [2]. However, although this 
process is essential in the synthesis of cholesterol, it also generates a number of non-
sterol molecules that play critical roles in many different cell processes by regulating key 
proteins post-translationally. In addition to its crucial role in membrane structure and 
properties, cholesterol has been described in the regulation of a number of cellular 
processes and pathways, including cancer biology and therapy [6,7,8]. The contribution 
of cholesterol in promoting cancer is well known and has been described for more than a 
century when John H. Webb suggested that cancer was due to the crystalization of 
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cholesterol from living cells [9]. Later observations confirmed the accumulation of 
cholesterol in tumors, suggesting that cholesterol is associated with the regulation of cell 
proliferation [10]. While the role of cholesterol in cancer has been considered previously 
[4,11,12], in this review we will focus primarily on the contribution of the non-sterol 
branch of the mevalonate pathway in cancer biology. In the mevalonate pathway acetyl-
CoA is converted to HMG CoA, which is then transformed into mevalonate catalyzed by 
HMG-CoA reductase [2]. The phosphorylation of mevalonate yields 5-
pyrophosphomevalonate, which is converted to isopentenyl pyrophosphate (IPP) (Figure 
1). IPP can be reversibly transformed to dimethylallyl pyrophosphate (DMAPP), and the 
combination of both IPP and DMAPP yields the 10-carbon isoprenoid geranyl 
pyrophosphate (GPP). The sequential addition of 1 or 2 more IPP units to GPP generates 
the 15-carbon and the 20-carbon isoprenoids farnesyl pyrophosphate (FPP) and the 
geranylgeranyl pyrophosphate (GGPP), respectively. FPP branches into the non-sterol 
pathways, which contribute to the generation of other derivatives such as ubiquinol, 
dolichol, and the sterol pathway via conversion into squalene by squalene synthase, 
which catalyzes the first committed step in cholesterol synthesis. As it can be inferred 
from this metabolic picture, the inhibition of HMG-CoA reductase by statins not only 
blunts cholesterol synthesis but also depress the generation of isoprenoids impairing 
protein prenylation. This dual function of statins underlies their cholesterol-independent 
effects in a number of pathologies, and provides the basis for the efficacy of statins in 
reducing cardiac events beyond their effect in reducing cholesterol levels [13,14]. As 
indicated above, mevastatin, the first characterized statin, is a natural compound and was 
identified from Penicillium Citrinum, a mold that infects the Japanese orange [1]. Many 
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statins are derived from fungi, such as lovastatin (Figure 2) or made synthetically such as 
atorvastatin (Figure 2). The efficacy to block HMGCoA reductase depends on the 
structure and physical properties of statins. All available statins are lipophylic except 
pravastatin, a natural statin derived from fungi, and have a side chain with either an open-
ring (acid) or closed-ring (lactone) structure. The latter is an inactive prodrug that is 
converted to the active form, -hydroxy-acid, by carboxyesterases in the liver. It has been 
shown that HMG-CoA reductase is bound about 1000 times more effectively by statins 
with open-ring structures than by its natural substrate, HMG-CoA and exhibit a high 
potency in blocking the mevalonate pathway [12]. Unlike other statins, the active 
hydroxy metabolites of atorvastatin, particularly the o-hydroxy derivative, exhibit the 
same enzymatic inhibition of HMGCoA reductase as the parental statin. In addition, the 
active o-hydroxy derivative of atorvastatin has been described to prevent cholesterol 
domain formation by an antioxidant mechanism [15]. 
In addition to the regulation of mevalonate, which impacts on the modulation of cell 
cholesterol levels and protein-prenylation, statins also affect other cellular processes 
including the inhibition of the proteasome pathway [16,17], cell adhesion, migration and 
invasion via inhibition of the interaction between the integrin lymphocyte function-
associated antigen 1 (LFA1) and intercellular adhesion molecule 1 (ICAM1) [18]. Giving 
the role of protein prenylation as a key mechanism involved in the regulation of cell 
differentiation, cell cycle progression and apoptosis by targeting specific proteins 
[19,20,21,22], in the following sections we will briefly describe the players involved in 
this important pathway which is of relevance in cancer cell biology. 
PROTEIN-PRENYLATION  
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As described above the mevalonate pathway is responsible not only for the synthesis of 
cholesterol but also for the generation of non-sterol isoprenoids, FPP and GGPP, which 
bind to and regulate target proteins in a process named protein prenylation (Figure 1). 
FPP and GGPP are covalently attached to cysteine residues in CaaX motifs at the C-
terminus of proteins, where C is a cysteine moiety next to two aliphatic residues with X 
being any aminoacid, leading to the farnesylation or geranylgeranylation of the target 
protein [23] (Figure 3). While farnesylation is catalyzed by farnesyltransferase (FTase), 
geranylgeranylation is catalyzed by two geranylgeranyltransferases, GGTase I and II. 
Once prenylated, proteins undergo postprenylation modifications, including the 
proteolytic processing that removes the aaX tripeptide catalyzed by the prenyl protease 
named Ras-converting enzyme 1 (RCE1) and the addition of a methyl group to the C-
terminal prenylcysteine catalyzed by the enzyme isoprenylcysteine carboxyl 
methyltransferase (ICMT) which uses S-adenosyl-L-methionine as methyl donor [24]. 
From a functional perspective, prenylation of proteins is viewed as a tool that promotes 
their membrane attachment, binding to other signaling proteins and afford protection 
against proteolytic degradation [25]. The functional role of these posttranslational 
modifications depends on the nature of the targeted protein. For relevance in this review, 
many prenylated proteins are involved in various aspects of carcinogenesis, including 
cellular proliferation, apoptosis, angiogenesis and metastasis [26,27]. For instance, 
prenylation of proteins such as Ras, lamin B or centromere proteins (e.g. CENP-E and 
CENP-F) play a critical role in the regulation of cellular proliferation, while the 
prenylation of Rac, Rho and protein tyrosine phosphatase, PTP4A3 modulate apoptosis, 
angiogenesis and metastasis, respectively. Thus, given the important function of protein 
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prenylation in the regulation of a number of steps involved in carcinogenesis, several 
enzymes involved in protein prenylation have been targeted pharmacologically to 
modulate cancer cell biology [28,29,30]. Besides the development of inhibitors for 
FTase, GGTase I and II, RCE1, ICMT, other pharmacological agents regulating protein 
prenylation at different levels have been developed for potential anticancer effects, 
including those targeting mevalonate pyrophosphate decarboxylase (sodium 
phenylacetate and sodium phenylbutyrate), IPP isomerase, FPP synthase 
(aminobisphosphonates) and FTase (FTIs) and GGTase (GGTIs) inhibitors. In addition, 
statins by inhibiting HMG-CoA reductase impact negatively on the generation of 
isoprenoids, including FPP and GGPP, which in turn, regulate protein prenylation. 
However, as described below, the outcome with single-agent inhibition, including statins, 
in cancer cell biology did not meet the predicted expectations based on preclinical 
experience [31], providing the rational for combination therapy targeting the mevalonate 
pathway. 
MONOTHERAPY VS COMBINATION THERAPY TARGETING THE 
MEVALONATE PATHWAY AS AN ANTICANCER STRATEGY 
Monotherapy 
Although the use of statins is prevalent because elevated total cholesterol and low density 
lipoproteins (LDL) levels are major risk factors for coronary heart disease [32], and in 
most cases safe, there can be side effects associated with statin use, such as myopathy 
and hepatotoxicity [33], which are commonly speculated to be due to the depletion of 
nonsterol components of the mevalonate pathway [34]. Furthermore, statin use does not 
always reduce plasma LDL to desired levels [35], which is particularly important to 
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mediate the therapeutic potential of statins in cardiovascular events [36,37,38]. LDL is 
the major cholesterol-carrying lipoprotein in the blood and the liver is the major organ for 
LDL clearance via mechanisms essentially mediated by LDL receptor expressed in 
hepatocytes. LDL-LDL receptor interaction is responsible for most of LDL removed 
from the circulation and LDL receptor deficiency is the major cause for familial 
hipercolesterolemia [39]. However, proteins that regulate LDL receptor 
posttranscriptionally determine the response to statin-mediated LDL receptor 
overexpression. For instance, PCSK9 is a protein that plays a critical role in post-
translational degradation of LDL receptor. PCSK9 is highly expressed in hepatocytes and 
small intestine and is a sterol-responsive gene, up-regulated by statins-mediated SREBP-
2 activation [40]. This may explain why many patients undergoing statin treatment to 
increase LDL receptor expression cannot always attain their therapeutic goals. 
Given the function of HMG-CoA reductase in the mevalonate pathway its inhibition by 
statins leads to a reduction of cellular FPP and GGPP levels, resulting in the impairment 
of protein prenylation. However, although such as dual function may account for the 
positive role of statins in regulating carcinogenesis, the chronic inhibition of HMG-CoA 
may lead to undesired effects in the mevalonate pathway, accounting for the dissociation 
between the effects observed in experimental models and clinical trials. For instance, 
HMG-CoA reductase levels are negatively regulated by complex transcriptional, 
translational and posttranslational feedback mechanisms controlled by both sterol and 
non-sterol products of the mevalonate pathway [2]. Reduction of isoprenoid and 
cholesterol levels by statins leads to upregulation of HMG-CoA reductase levels and, 
eventually, development of resistance [2,41].  In vitro mechanistic studies of statins used 
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significantly higher concentrations than those that were therapeutically achievable in 
phase I trials or with standard anticholesterol dosing. Dose-limiting toxicities, including 
gastrointestinal side effects, myelotoxicity, myalgias, elevation of creatine phosphokinase 
and hepatotoxicity, precluded further dose increase in clinical trials [31]. Moreover, 
studies in experimental models indicated that statin effects are mostly conferred through a 
reduction in geranylgeranylation (specifically, geranylgeranylation of Rho and Rac) 
rather than a reduction in farnesylation [20,42]. Similar to the use of statins as 
monotherapy, sodium phenylbutyrate, which inhibits mevalonic pyrophosphate 
decarboxylase, exhibited limited activity in clinical trials at doses that were effective in 
experimental studies [43,44]. However, undesired neurotoxic effects prevented the 
possibility of using higher doses in clinical trials. Moreover, by inhibiting Ras 
farnesylation, FTIs inhibit multiple downstream pathways, such as Raf–MAPK kinases-
ERK or Akt, Tiam1–Rac, which are involved in cellular survival and proliferation 
[45,46]. However, despite promising preclinical evidence, the antitumor activity of FTIs 
as single agents in most solid tumors has been disappointing, perhaps with the exception 
of hematological malignancies, in which FTIs exhibited a promising response [47]. A 
plausible explanation for the lack of efficiency of FTIs in cancer therapy is the 
occurrence of cross-prenylation of specific target proteins. For instance, it has been 
shown that both K-Ras and N-Ras can also be geranylgeranylated by GGTase I as an 
alternative method of prenylation [48], which underlies the refractoriness to the inhibition 
of K- and N-Ras farnesylation by FTIs. Unlike K-Ras and N-Ras, H-Ras is only 
farnesylated and cannot be geranylgeranylated. Moreover, K- or N-Ras-transformed cells 
exhibit decreased response to FTIs compared to H-Ras-transformed cells during 
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carcinogenesis, and it has been shown in a mouse model dependent on K-Ras that protein 
farnesylation was not required for lung carcinogenesis [49]. Thus, these findings 
underscore that although FTIs focused mainly on H-Ras activation, it is increasingly 
recognized that K-Ras, N-Ras and other proteins are more important than H-Ras in 
carcinogenesis. 
The conversion of FPP into squalene by squalene synthase (SS) serves as the first 
committted step towards the synthesis of cholesterol, which requires extensive oxygen 
consumption. Inhibition of SS has attracted much interest as a pharmacological target as 
it implies the inhibition of cholesterol synthesis without depressing isoprenoid levels, and 
consequently, various compounds have been identified as inhibitors [50,51]. For instance, 
lapaquistat (TAK-475, Takeda), a SS inhibitor, progressed to phase III clinical trials, but 
studies were discontinued after the US Food and Drug Administration recommended 
suspension of studies with high-dose (100 mg/kg) monotherapy due to hepatotoxicity 
manifested as elevated levels of liver transaminases [51]. However, it is uncertain 
whether this outcome was due to an enzyme inhibitory class effect or whether it was 
specific to the drug. Unlike statins, inhibition of SS can result in the accumulation of both 
FPP and FPP metabolites, such as farnesol-derived dicarboxylic acids [52], which could 
contribute to the hepatotoxic effects observed with the high-dose monotherapy of 
lapaquistat. For instante, farnesol itself can be proapoptotic at high concentrations [53]. 
Interestingly, the combination therapy of SS inhibitors (e.g. lapaquistat) with statins 
would be expected to avoid potential accumulation of FPP metabolites. For instance, 
combination therapy of lapaquistat and statins showed additional LDL reduction 
compared with statins alone [51]. Of relevance, T-91485, the active metabolite of 
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lapaquistat, is capable of preventing statin-induced myotoxicity in a human skeletal 
muscle cell model [54]. Moreover, lapaquistat is able to prevent statin-induced 
myotoxicity in a guinea pig model [55]. In addition to the expected cholesterol depletion, 
other SS inhibitors have shown the potential for added benefits due to decreased 
triglyceride biosynthesis [56], most likely due to a farnesol-mediated mechanism [57]. 
Nitrogenous bisphosphonates (NBP; e.g., zoledronate and alendronate) are a second class 
of clinical drugs targeting the mevalonate pathway, and they are used for treatment of 
bone-related disorders such as osteoporosis. NBPs function by inhibition of FPP 
synthase, resultingin depletion of cellular levels of FPP and other downstream 
isoprenoids [58]. Bisphosphonates may be regarded as analogs of diphosphates, in which 
the central bridging oxygen atom (P-O-P) has been replaced with a carbon (P-C-P). This 
results in increased metabolic stability and allows chemical functionalization of the 
bisphosphonate core. Furthermore, the P-C-P linkage combined with an α-hydroxy group 
facilitates bone targeting [59], although other reports indicated the ability of nitrogenous 
bisphosphonates to decrease cholesterol levels in patients with osteoporosis and 
hyperlipidemias [60]. In addition, recent findings indicated the ability of statins and 
aminobisphosphonates to extend longevity in progeria [61]. Several human progerias, 
including Hutchinson-Gilford progeria syndrome (HGPS), are caused by the 
accumulation at the nuclear envelope of farnesylated forms of truncated prelamin A, 
which can be prevented by FTIs. However, alternative prenylation of laminA by 
geranylgeranyltransferase in the setting of FTase inhibition, could explain the low 
efficiency of FTIs in ameliorating the phenotypes of progeroid mouse models. 
Interestingly, recent studies show that a combination of statins and 
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aminobisphosphonates efficiently inhibits both farnesylation and geranylgeranylation of 
progerin and prelamin A and markedly improves the aging-like phenotypes of a mouse 
model of human premature aging [61]. 
Thus, since metabolites of the mevalonate pathway are a key tool for the posttranslational 
modification of proteins, their modulation may have far reaching consequences other than 
decreasing cholesterol levels, which ultimately may be of relevance in many 
pathophysiological processes including cancer biology and therapy.  
Combination therapy 
Given these pitfalls in the use of montherapy targeting the mevalonate pathway as a 
strategy for fighting cancer, other alternatives include combination therapy aiming at 
simultaneous inhibition of both geranylgeranylation and farnesylation, or concomitant 
reduction of isoprenoid availability and inhibition of prenylation and postprenylation 
enzymes.  
Combinations of FTIs and GGTIs have been shown to induce synergistic cytotoxicity, 
apoptosis and disruption of Ras–MAPK signaling. In different myeloma cells, which 
often exhibit K- and N-Ras mutations, FTIs or GGTIs separately failed to block 
prenylation of K- and N-Ras, while GGTI–FTI combinations inhibited prenylation of all 
Ras isoforms and induced a more potent blockade of the Ras–MAPK signaling cascade 
[62]. GGTI–FTI combinations synergistically inhibit proliferation of multiple myeloma 
cell lines and primary cells, and induce apoptosis. Interestingly, dual prenylation 
inhibitors (DPIs) that block both FTase and GGTase enzymatic activities have been 
shown to induce apoptosis in PSN-1 pancreatic tumor cells by blocking K-Ras 
prenylation compared to either FTI or GGTI agents alone [63]. H- N- and K-Ras 
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prenylation exhibit differential susceptibility to FTI vs GGTIs inhibition. For instance, H 
and N-Ras prenynation is effectively inhibited by FTIs and only partially by GGTIs, 
whereas K-Ras prenylation requires both FTIs and GGTIs inhibition [64]. In addition, 
Rho proteins can also be alternatively prenylated, and FTIs alone are unable to inhibit 
Rho prenylation, whereas GGTI–FTI combinations are able to inhibit it effectively [62]. 
Thus, combined inhibition of geranylgeranylation and farnesylation can overcome the 
resistance conferred by cross-prenylation, thus potentiating the activity of either FTIs or 
GGTIs alone. Although FTI and GGTI combinations have demonstrated enhanced 
antiproliferative and proapoptotic activities in vitro (relative to FTI monotherapy), the 
concern with this particular combination therapy relates to its cytotoxicity, which is 
mainly due to the GGTIs. Indeed, DPIs which simultaneously inhibit GGTase I and 
FTase can overcome the toxicity of GGTIs and GGTI–FTI combinations. Interestingly, 
agents that mimic the CaaX moiety have been shown to exhibit significant inhibitory 
activity against GGTase I (besides FTase), and are well tolerated in Phase I and II clinical 
trials [65,66], suggesting they may be promising agents for cancer cell therapy.  
Moreover, by inhibiting the mevalonate pathway and reducing the biosynthesis of 
cholesterol and isoprenoids, statins interfere with membrane synthesis and decrease the 
N-glycosylation of growth factor receptors such as the insulin-like growth factor receptor 
[41]. Although inhibition of protein farnesylation by FTIs might lead to increased levels 
of FPP, which can be used for the synthesis of cholesterol and dolichyl phosphate, the 
addition of statins would be expected to prevent this alternative pathway. Therefore, 
combinations of statins and FTIs act synergistically to inhibit malignant cell proliferation 
and induce apoptosis, causing a more effective inhibition of prenylation modifications by 
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decreasing isoprenoid levels and by inhibiting geranylgeranylation and farnesylation. For 
instance, in multiple myeloma cells, FTIs potentiate the ability of lovastatin to inhibit 
Rho, K- and N-Ras prenylation and MEK-MAPK activation, resulting in impaired cell 
migration and enhanced apoptosis [62]. In vitro doses of lovastatin combined with FTIs 
have been demonstrated to be at least as effective as double doses of lovastatin 
administered alone, indicating that statin–FTI combinations might be of relevance to 
achieve therapeutic effects without the potential toxicity of using higher doses of statins 
alone. 
Since one of the mechanisms of resistance to statins is upregulation of HMG-CoA 
reductase levels, tumor cells exhibit a relative resistance of HMG-CoA reductase to sterol 
feedback mechanisms but are particularly sensitive to isoprenoid-mediated suppression 
[41]. Therefore, the combination of isoprenoids with statins can counteract the statin-
induced upregulation of HMG-CoA reductase levels, leading to a more potent inhibition 
of the mevalonate pathway. For instance, it has been shown that the combination of 
lovastatin and the isoprenoid γ-tocotrienol synergistically inhibits growth of human 
DU145 and LNCaP prostate carcinoma and murine B16 melanoma cells [42]. 
In addition to the beneficial combination of statins and aminobisphosphonates in 
premature aging and progeria [61], there is experimental data to support their synergistic 
effects in anticancer therapy, reflected by more efficient apoptosis induction and reduced 
tumor cell invasiveness in vitro as well as decreased in vivo metastasis [67,68]. The 
underlying mechanisms for this synergistic action of statins and aminobisphosphonates 
derive from their individual effect on the mevalonate pathway, namely, inhibition of 
HMG-CoA reductase (by statins) and FPP synthase and IPP isomerase (by 
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aminobisphosphonates), leading to decreased FPP synthesis and a reduction in 
cholesterol and dolichyl phosphate synthesis, which impact on the rate of protein 
prenylation and postprenylation and alteration in membrane dynamics, which in turn 
regulate different growth factors receptors [41]. In addition, the beneficial effect of the 
combination of statins and aminobisphosphonates as anticancer therapy may be exerted 
through mechanisms independent of the mevalonate pathway. While statins regulate cell 
invasion, migration and adhesion via modulation of LFA1 and ICAM1 [18], 
bisphosphonates contribute to the regulation of these processes by decreasing expression 
of integrins (e.g. av3 integrin) and inhibiting angiogenic factors such as VEGF, PDGF 
and FGF [69,70,71]. 
Consistent with the essential role of prenylation in protein biology and function, targeting 
this pathway may be also of relevance in cancer biology, particularly in combination with 
agents that inhibit postprenylation events. As alluded above, prenylated proteins undergo 
proteolytic processing such as the removal of the aaX tripeptide catalyzed by RCE1 and 
the addition of a methyl group catalyzed by ICMT. While inhibition of RCE1 has 
moderate antitumor effects, this process sensitizes tumor cells to FTI treatment. For 
instance, FTIs are more efficient in inhibiting cell growth of fibroblasts and skin 
carcinoma cells that are deficient in RCE1 activity [72]. Furthermore, although inhibition 
of ICMT alone does not completely abrogate downstream Ras signaling, such ERK1/2 
and Akt activation [73,28], which is expected to have a minor role as anticancer strategy, 
the combination of ICMT inhibitors with FTIs or GGTIs or statins may be more effective 
in suppressing the growth of Ras-dependent tumors.  
HEDGEHOG, CHOLESTEROL AND CANCER 
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Hedgehog (Hh) is a morphogen essential for embryonic development, but its 
overactivation is recognized as a key mechanism that fosters cancer development [74]. Of 
relevance here, there is evidence linking the Hh signaling with the mevalonate pathway, 
and that cholesterol is a key regulator of the Hh pathway. The Hh signaling pathway was 
first described in genetic studies of embryonic segmentation in Drosophila. However, it is 
highly conserved from insects to vertebrates. In mammals, three hedgehog homologs, 
Sonic (Shh), Indian (Ihh), and Desert hedgehog (Dsh) are known. Shh is the most 
commonly expressed and the best characterized homolog; it is crucial for the 
development and maintenance of the nervous system, axial skeleton, lungs, skin, hair, 
and stem cell populations. Shh is synthesized as a 45 kDa precursor protein that is auto-
catalytically cleaved and covalently modified by palmitate and cholesterol [75]. Once 
Shh is secreted it binds to its receptor Patched 1 (Ptch1), a 12-transmembrane receptor for 
Shh, which functions as the key inhibitor of Shh signaling (Figure 4). Ptch1 inhibits Shh 
signaling by inhibiting activity of the 7-transmembrane receptor, Smoothened (Smo), a 
positive regulator of signaling [76]. The repression of Smo by Ptch1 inactivates 
downstream Shh effectors, namely the glioma-associated (Gli) family of transcription 
factors. The Gli transcription factors (Gli1, Gli2, Gli3) control the expression of Shh 
target genes including Ptch1 and Gli1 themselves, which provide negative and positive 
feedback regulation of Hh signaling, respectively. Binding of the Shh ligand to Ptch1 
causes both Shh and Ptch1 to be sequestered into endocytic vesicles, which relieves the 
inhibition of Smo. As transcription factors, Gli can regulate target gene expression by 
direct association with a consensus binding site (5′-tgggtggtc-3′) located in the promoter 
region of the target genes. Direct downstream targets of Hh signaling include Bcl2, 
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Cyclin D1, Cyclin D2, FoxM1, FoxE1, Hip, and PDGFR among others [77,78]. As many 
of these genes are directly involved in cell cycle regulation (cyclins) and cell survival 
(Bcl2), their activation accounts for the  contribution of Hh to tumor cell proliferation and 
hence cancer development. 
The cholesterol connection to the Hh pathway is exerted at different levels. For instance, 
the Hh proteins are the only known family of proteins that have covalently bound 
cholesterol. In addition, the 12-transmembrane domains of Ptch1 include a five-
transmembrane sterol-sensing domain that is also observed in several other proteins that 
participate in cholesterol metabolism, including SCAP [2]. Recent evidence suggested 
that Ptch1 could function as a mechanism for the efflux of cholesterol from cells, and that 
this novel action could contribute to Smo repression [79]. In the presence of cholesterol 
the inhibition of Ptch1 on Smo is relieved allowing the endocytic trafficking of Smo and 
Ptch1 to stimulate the transcriptional activation of target genes by the transcription factor 
Gli (Figure 4). This effect of cholesterol may be specific to the presence of the sterol in 
the plasma membrane, which may induce a conformational change in Ptch1 that alters its 
intracellular trafficking to allow Smo signaling. However, when cholesterol levels are 
low, as expected following the administration of statins or caused by genetic defects in 
the mevalonate pathway, the binding of Hh to Ptch1 fails to activate Smo, presumably 
due to insufficient membrane cholesterol to induce conformational change in Ptch1. 
Moreover, various enzymatic defects in the final steps of the cholesterol biosynthesis 
pathway give rise to multiple developmental anomalies due to impaired Hh signalling. 
For instance, vitamin D3 is formed by the action of ultraviolet light on 7-
dehydrocholesterol, an immediate precursor of cholesterol and the sterol that accumulates 
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in a relatively common genetic disorder, Smith–Lemli–Opitz syndrome (SLOS). 
Although predisposition for tumor development is not considered a feature associated 
with SLOS, a recent report described the first observed association of SLOS with 
malignant intracranial germ-cell tumor [80]. 
It is known that constitutive activation of the Hh pathway leads to tumorigenesis such as 
that seen in basal cell carcinomas and medulloblastoma. A variety of other human 
cancers, including brain, gastrointestinal, lung, breast and prostate cancers, also 
demonstrate inappropriate activation of this pathway [74]. Paracrine Hh signaling from 
the tumor to the surrounding stroma was recently shown to promote tumorigenesis. 
Moreover, this pathway has also been shown to regulate proliferation of cancer stem cells 
and to increase tumor invasiveness, indicating that targeted inhibition of Hh signaling 
may be effective in the treatment and prevention of many types of human cancers [81]. 
Based on these findings it could be hypothesized that statins may regulate Hh signaling 
pathway via their cholesterol lowering effects, which could have a putative impact on 
cancer development. However, this process needs adequate testing and validation in 
experimental models.    
STATINS, COLORECTAL AND PANCREATIC CANCER 
Although the effects of statins in cancer cell therapy have provided mixed results in some 
malignancies (e.g. breast cancer, melanoma), in the following section we will focus on 
specific types of cancer that have a major impact on health and in which statins use have 
shown more definitive outcomes. Colorectal cancer (CRC) is one of the most common 
cancers and the third cause of cancer-related deaths. While the causes leading to CRC are 
not completely understood, genetic factors and chronic intestinal inflammation (e.g. 
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inflammatory bowel disease) are major risk factors for CRC. Aberrant DNA methylation 
of CpG islands in the promoter regions of many genes occurs in human CRC and is 
associated with tumour suppressor gene silencing [82]. In addition, types of CRC that 
show extensive DNA methylation in the promoter regions of specific genes are associated 
with chemotherapy resistance [83]. Thus, given the health impact and death burden of 
CRC a better therapeutic approach is needed. In this regard, although the role of statins in 
CRC is controversial, there has been recent developments and evidence providing some 
hints for the beneficial effects of statins in CRC [84]. As described above, statins inhibit 
the key enzyme in the cholesterol-synthesis pathway, thereby reducing serum cholesterol 
levels; but the mevalonate pathway also generates intermediates that act as growth factors 
and are involved in cell survival pathways (Figure 1). Those dual and conflicting roles 
may help explain the mixed results of epidemiological studies on statins’ effect on CRC 
[84]. Nevertheless, current data link statins with bone morphogenic protein (BMP) 
pathway, which regulates intestinal epithelial homoeostasis, differentiation, stem cell 
activation and CRC [85,86,87,88,89]. For instance, recent evidence indicated that statins 
inhibit cellular proliferation and induce apoptosis in CRC cells and in animal models via 
BMP regulation [90,91]. Indeed, the screening of compounds for their ability to enhance 
BMP expression for eventual use to enhance bone formation identified statins as the one 
of the most active agents [92]. Moreover, a recent study demonstrates the ability of 
statins to increase the chemosensitivity of CRC cells by inducing epigenetic 
reprogramming and reducing colorectal cancer cell stemness via the BMP [93]. Statins 
act as DNA methyltransferase inhibitors that upon demethylation of the BMP2 promoter 
activate BMP signaling, inducing differentiation of CRC cells and reducing their 
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stemness. Thus this recent evidence indicates that statins may be able to be used as 
differentiating agents in combined or adjuvant therapy in CRC exhibiting the CpG island 
methylator phenotype. Moreover, resistance of CRC to current chemotherapy relates to 
mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS). 
Monoclonal antibodies (e.g. cetuximab and panitumumab) that target the epidermal 
growth factor receptor (EGFR) are effective in terms of response rate and progression-
free survival in combination with standard cytotoxic chemotherapy in metastatic CRC 
[94,95]. However, mutations in KRAS, which occur in about 40% of CRC patients, is a 
major negative predictor for treatment response in patients receiving cetuximab [96,97]. 
Interestingly, a recent study reported that simvastatin overcomes cetuximab resistance in 
CRC cells with KRAS mutations by modulating BRAF activity and inducing apoptosis 
[98]. Despite these promising outcomes in preclinical studies, the recommendation of 
statin use for CRC in clinical practice is still far [99,100]. The contradictory results 
illustrate the central problem in evaluating claims for and against statins’ potential as 
chemopreventive therapy, as most studies used data that are not specific for evaluating 
statins but rather are part of large epidemiological datasets, while other studies that found 
no association between statin usage and CRC need to take in consideration the time of 
statin usage and the age of patients.  
Although somewhat lower compared to CRC, pancreatic cancer is still a major cause of 
cancer related deaths, particularly in developed countries [101]. The incidence and the 
failure of conventional chemotherapy to reduce the mortality associated with pancreatic 
cancer, dictate the need to identify and develop agents for pancreatic cancer 
chemoprevention and treatment. As with CRC, the association of statins with pancreatic 
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cancer risk is still unsettled and at variance with the findings reported in experimental 
approaches. For instance, antiproliferative effects of statins have been demonstrated in a 
number of in vitro as well as in vivo studies on pancreatic cancer cell lines regardless of 
Ras mutations [20,102,103,104]. Moreover, statins have been shown to sensitize 
pancreatic cancer cells to chemotherapeutic drugs by targeting the P2X7-Akt axis [105]. 
However, epidemiological studies evaluating the relationship between the use of statins 
and the risk of pancreatic cancer gave inconsistent findings. Some studies reported that 
the use of these drugs is inversely related to the risk of pancreatic cancer, whereas other 
studies found no or positive associations [106,107]. While several pitfalls may contribute 
to this unestablished scenario, including improper study designs, short follow-ups, or 
insufficient control for potential confounders, the type of statins used in these studies may 
be a critical factor. In addition to the lipophilicity of statins, other pharmacokinetic and 
pharmacodynamic properties might be responsible for differences in anticancer properties 
of individual statins. Indeed, substantial differences in antiproliferative effects on 
experimental pancreatic cancer cell lines with different statins used for clinical purposes 
have been described [108]. In this relevant study, it was found that the least efficient 
statins were pravastatin and atorvastatin, whereas rosuvastatin (despite its low 
lipophilicity) and cerivastatin were the most effective, and all statins (except pravastatin) 
inhibited intracellular Ras protein translocation [108]. Thus, these findings illustrate the 
need for proper design and controlled clinical studies to critically evaluate the role of 
statins in pancreatic cancer.  
STATINS IN METABOLIC LIVER DISEASES AND HEPATOCELLULAR 
CARCINOMA 
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Fatty liver disease is a common cause of chronic liver injury in industrialized countries, 
and encompasses a spectrum of disorders ranging from fatty liver (steatosis) to 
steatohepatitis that can progress to cirrhosis and eventually hepatocellular carcinoma 
(HCC). Due to the rising prevalence of obesity and type II diabetes worldwide metabolic 
liver diseases, in particular, nonalcoholic steatohepatitis (NASH) constitutes a global 
health concern. Although the mechanisms underlying NASH are not fully undertood it is 
known that the onset of hepatic steatosis sensitizes to secondary factors (e.g. hypoxia, 
inflammatory cytokines) leading to the characteristic features of NASH such as oxidative 
stress, inflammation, hepatocellular death and fibrosis. Moreover, disease can progress 
towards HCC and obesity and high body mass index (BMI) have been shown to increase 
the risk for cancer, particularly HCC [109]. For instance, men with a BMI of 35-40 
exhibited a staggering 4-5-fold increase in relative HCC risk [109]. HCC is one of the 
most frequent tumors worldwide and is generally a fatal disease, as few patients are 
amenable to surgery because of late HCC diagnosis. Moreover, current treatment options 
offer no or very low survival in HCC patients not suitable for resection [110,111]. Hence, 
investigations of molecular mechanisms leading to HCC development and progression is 
required to identify new targets for its early diagnosis, chemoprevention and treatment. 
Aberrant lipogenesis is key for metabolic liver disease and HCC, with reports indicating 
upregulation of a number of lipogenic enzymes at the mRNA and protein level in human 
HCC [112,113,114]. Consistent with these findings, a recent report indicated increased 
lipogenic enzymes and activities in human HCC and cell lines, including the stimulation 
of cholesterol levels in HCC tissues [114]. Moreover, an association between liver fat 
accumulation and HCC development has been long known [115,116]. Concerning the 
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evolution of simple steatosis to more advanced stages of NASH, a novel role for 
cholesterol has emerged, particularly with its trafficking to mitochondrial membranes 
[117]. Indeed, mitochondrial cholesterol accumulation has been shown to sensitize to 
inflammatory cytokines, contributing to the transition from steatosis to steatohepatitis by 
regulating mitochondrial antioxidant defense mechanisms and mitochondrial membrane 
permeabilization [118,119]. Interestingly, in genetic models of obesity, treatment with 
atorvastatin prevented the increase of cholesterol in mitochondria and the sensitization of 
ob/ob mice to LPS-mediated liver injury [118]. In HCC cell lines and heterotopic 
xenografts HCC it has been shown that the increased trafficking of cholesterol to 
mitochonria modulates chemotherapy sensitivity, and that in vivo treatment with 
atorvastatin sensitized nude mice harboring HCC tumors to doxorubicin, suggesting that 
cholesterol play a role in HCC and that the use of statins may be of relevance in HCC 
[8,120]. Moreover, recent findings further showed the potential therapeutic effects of 
statins in hepatic carcinogenesis involving mechanisms related to decreased matrix 
metalloproteinase activity or inhibition of autophagy [121,122,123]. However, the 
experience of statins in human HCC has been conflicting. This is probably because in 
many trials, which examined the association between statins and cancer, including HCC, 
the impact of statins in cancer was a secondary end point. For instance, a population-
based cohort study using the Danish Cancer Registry for the period of 1989-2002 found 
not significant increased or decreased rate ratios for any of the studied site-specific 
cancers including liver [124]. However, a systematic review of 17 randomised controlled 
trials, 10 cohort studies, and 15 case-control studies indicated that while statins had no 
effect on the overall incidence of lung or breast cancer, they seemed to protect from liver 
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cancer [125]. Moreover, a population-based case–control study in Taiwan over a 
thounsand cases of liver cancer and matched controls, indicated that the use of statins 
may reduce the risk of liver cancer [126]. However, trials addressing the potential 
therapeutic effect of statins (pravastatin) indicated a potential beneficial role in 
modulating HCC progression. For example, a clinical trial of 91 patients with advanced 
HCC reported that the median survival of 18 months of patients on pravastatin was twice 
that of controls [127]. Although this effect was not confirmed in a shorter cohort (51 
patients) [128], another trial with 131 patients showed that the combination of 
chemoembolization with pravastatin improved survival of patients with advanced HCC in 
comparison to patients receiving chemoembolization alone [129]. Furthermore, a recent 
study using a large cohort of diabetics, whose risk of HCC is higher than average, 
concluded that the use of statins is associated with a significant reduction in the risk of 
HCC among patients with diabetes [130]. Collectively, these clinical studies strongly 
suggest the need to further explore the potential therapeutic relevance of statins alone or 
in combination with other treatments in HCC. 
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CONCLUDING REMARKS 
Cancer-related morbidity is one of the leading causes of deaths in the world. Due to the 
social and health impact research on cellular and molecular pathways driving 
oncogenesis and carcinogenesis is one of the most active areas of biomedical 
investigation with the aim to characterize novel treatment options. Although the role of 
cholesterol as a cancer-promoting factor has been known for more than a century, the 
interest and potential relevance of cholesterol metabolism in cancer have increased with 
the use of statins. Emerging data in experimental models suggest that cholesterol 
upregulation promotes carcinogenesis. Cholesterol is a critical component of membrane 
bilayers that determine the structural and functional properties of cellular membranes. Its 
enrichment in particular organelles, such as mitochondria, may have an important impact 
in the regulation of mitochondrial function, cell death susceptibility and response to 
chemotherapy. However, the biological effects of statins may be broader than simply 
reducing cholesterol levels. By inhibiting HMG-CoA reductase statins impact negatively 
on the generation of isoprenoids, which in turn, regulate protein prenylation affecting a 
number of critical pathways in the regulation of cell cycle, proliferation, adhesion, which 
would be expected to regulate carcinogenesis. Thus, while statins have the potential of 
regulating widespread factors many of them essential for oncogenesis, a further 
understanding on the molecular processes promoting specific types of cancers may give 
valuable insights to design combination therapy to improve cancer therapy. For instance, 
in the case of HCC further research is needed to evaluate whether targeting the 
mevalonate pathway, using inhibitors that block different steps in the pathway, in 
combination with sorafenib may be more effective than either treatment alone.  
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ABBREVIATIONS 
BMI: body mass index 
BMP: bone morphogenetic protein 
BRAF: v-raf murine sarcoma viral oncogene homolog B1  
CRC: Colorectal cancer 
DMAPP: dimethylallyl pyrophosphate 
DPI: dual prenylation inhibitor 
Dsh: Desert hedgehog  
EGFR: epidermal growth factor receptor 
ERK: extracellular-signal-regulated kinase 
FGF: fibroblast growth factor 
FoxE1: forkhead box E1  
FoxM1: forkhead box M1  
FPP: farnesyl pyrophosphate  
FT: farnesyltransferase 
GGPP: geranylgeranyl pyrophosphate 
GGT: geranylgeranyl transferase 
Gli: glioma-associated 
GPP: geranyl pyrophosphate 
HCC: hepatocellular carcinoma 
HGPS: Hutchinson-Gilford progeria syndrome 
Hh: Hedgehog  
Hip: hedgehog-interacting protein 
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HMG-CoA : hydroxymethylglutaryl-CoA 
ICAM1: intercellular adhesion molecule 1 
ICMT: isoprenylcysteine carboxyl methyltransferase  
Ihh: Indian hedgehog KRAS 
IPP: isopentenyl pyrophosphate  
LFA1: lymphocyte function-associated antigen 1 
MAPK: mitogen activated protein kinase  
NASH: non-alcoholic steatohepatitis 
NBP: Nitrogenous bisphosphonate 
P2X7: purinergic receptor 
PCSK9: Proprotein convertase subtilisin/kexin type 9 
PDGF: platelet-derived growth factor  
Ptch1: Patched 1  
RCE1: Ras-converting enzyme 1 
Shh: Sonic hedgehog  
SLOS:  Smith–Lemli–Opitz syndrome 
Smo:  Smoothened 
SS: squalene synthase 
VEGF: Vascular endothelial growth factor 
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